相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy
Henning Hanken et al.
CLINICAL ORAL INVESTIGATIONS (2016)
Platelet Transfusion: A Clinical Practice Guideline From the AABB
Richard M. Kaufman et al.
ANNALS OF INTERNAL MEDICINE (2015)
Practical management of myelofibrosis with ruxolitinib
P. J. Ho et al.
INTERNAL MEDICINE JOURNAL (2015)
Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort
Elizabeth M. Kander et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib
R. A. Abdelrahman et al.
LEUKEMIA (2015)
Platelet transfusion: a systematic review of the clinical evidence
Ambuj Kumar et al.
TRANSFUSION (2015)
Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension
Matthew Yan et al.
Clinical Lymphoma Myeloma & Leukemia (2014)
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (A-GHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.)
Stephan Kreher et al.
ANNALS OF HEMATOLOGY (2014)
A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms
Raajit Rampal et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
Lamia Lamrani et al.
BLOOD (2014)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit Rampal et al.
BLOOD (2014)
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
N. van Es et al.
BLOOD (2014)
The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology
Mike A. Laffan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
A Phase 2 Study of Ruxolitinib, an Oral JAK1 and JAK2 Inhibitor, in Patients With Advanced Polycythemia Vera Who Are Refractory or Intolerant to Hydroxyurea
Srdan Verstovsek et al.
CANCER (2014)
New oral anticoagulants in patients with atrial fibrillation Reply
Christian T. Ruff et al.
LANCET (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation
Fabio P. S. Santos et al.
LEUKEMIA & LYMPHOMA (2014)
JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms
S. Leah Etheridge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR)
Charles E. Mahan et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis
Marc Carrier et al.
THROMBOSIS RESEARCH (2014)
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Srdan Verstovsek et al.
ONCOTARGETS AND THERAPY (2014)
Dysfunction of the PI3 kinase/Rap1/integrin αIIbβ3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia
Samantha F. Moore et al.
BLOOD (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
Heinz Gisslinger et al.
BLOOD (2013)
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2013)
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Moshe Talpaz et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Practical management of patients with myelofibrosis receiving ruxolitinib
Claire Harrison et al.
EXPERT REVIEW OF HEMATOLOGY (2013)
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
Martin H. Prins et al.
THROMBOSIS JOURNAL (2013)
Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism
Martin H. Prins et al.
THROMBOSIS JOURNAL (2013)
Association of Oesophageal Varices and Splanchnic Vein Thromboses in Patients with JAK2-Positive Myeloproliferative Neoplasms: Presentation of Two Cases and Data from a Retrospective Analysis
Cornelia S. Link et al.
CASE REPORTS IN ONCOLOGY (2013)
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2012)
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)
Nelli Bejanyan et al.
CANCER (2012)
Venous thromboembolism in the hematologic malignancies
Anna Falanga et al.
CURRENT OPINION IN ONCOLOGY (2012)
A Systematic Review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy
D. E. Trigg et al.
HAEMOPHILIA (2012)
Introduction to the revised American Association for the Study of Liver Diseases position paper on acute liver failure 2011
William M. Lee et al.
HEPATOLOGY (2012)
An acquired factor VIII inhibitor in a myeloproliferative neoplasm presenting with severe retroperitoneal hemorrhage
Claudia Vener et al.
LEUKEMIA & LYMPHOMA (2012)
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2012)
Ruxolitinib for Myelofibrosis
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: A meta-analysis of 5 randomized trials in non-cancer and cancer patients
Silvy Laporte et al.
THROMBOSIS RESEARCH (2012)
Rituximab for managing acquired hemophilia A in a case of chronic neutrophilic leukemia with the JAK2 kinase V617F mutation
Shinsaku Imashuku et al.
JOURNAL OF BLOOD MEDICINE (2012)
Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism
Alina Andras et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Acquired hemophilia: We now see it with myeloproliferative neoplasms
Marina Kremyanskaya et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Amina Haouala et al.
BLOOD (2011)
JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients
Marina Panova-Noeva et al.
BLOOD (2011)
How I treat the acquired von Willebrand syndrome
Andreas Tiede et al.
BLOOD (2011)
Guidelines for the laboratory investigation of heritable disorders of platelet function
Paul Harrison et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Genetics of the myeloproliferative neoplasms
Omar Abdel-Wahab
CURRENT OPINION IN HEMATOLOGY (2011)
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
O. Abdel-Wahab et al.
LEUKEMIA (2011)
Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance
Giancarlo Castaman et al.
THROMBOSIS AND HAEMOSTASIS (2011)
The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis
D. W. Orr et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Polycythemia vera-associated acquired von Willebrand syndrome despite near-normal platelet count
Ayaew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Thrombosis in primary myelofibrosis: incidence and risk factors
Tiziano Barbui et al.
BLOOD (2010)
Thrombohemorrhagic complications of myeloproliferative disorders
Emmanouil Papadakis et al.
BLOOD REVIEWS (2010)
Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms
Jerome Duchemin et al.
THROMBOSIS RESEARCH (2010)
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis
Francesco Dentali et al.
BLOOD (2009)
JAK2V617F mutation in patients with arterial thrombosis in the absence of overt myeloproliferative disease
F. Dentali et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
The natural history and treatment outcome of blast phase BCR-ABL(-) myeloproliferative neoplasms
Constantine S. Tam et al.
BLOOD (2008)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia:: a retrospective survey
Marco Ruggeri et al.
BLOOD (2008)
Hemorrhagic complications of anticoagulant and thrombolytic treatment
Sam Schulman et al.
CHEST (2008)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study
A. Tiede et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science
O. Kilpivaara et al.
LEUKEMIA (2008)
Intensive care of patients with acute liver failure: Recommendations of the US Acute Liver Failure Study Group
R. Todd Stravitz et al.
CRITICAL CARE MEDICINE (2007)
The use of recombinant activated factor VII in congenital and acquired von Willebrand disease
Massimo Franchini et al.
BLOOD COAGULATION & FIBRINOLYSIS (2006)
The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders
Jan J. Michiels et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Long-term outcome of 231 patients with essential thrombocythemia - Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia
CS Chim et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys
AB Federici
BLOOD COAGULATION & FIBRINOLYSIS (2005)
Anagrelide for thrombocytosis in myeloproliferative disorders -: A prospective study to assess efficacy and adverse event profile
M Steurer et al.
CANCER (2004)
Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia
V Afshar-Kharghan et al.
BLOOD COAGULATION & FIBRINOLYSIS (2004)
Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization
KJ Pasi et al.
HAEMOPHILIA (2004)
Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: A randomized prospective clinical study
G Carter et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
An acquired factor VIII inhibitor in association with a myeloproliferative/myelodysplastic disorder presenting with severe subcutaneous haemorrhage
T Biss et al.
HAEMOPHILIA (2003)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients
T Bachleitner-Hofmann et al.
THROMBOSIS RESEARCH (2003)
Acquired von Willebrand syndrome: Experience from 2 years in a single laboratory compared with data from the literature and an International Registry
U Budde et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2002)
High-dose DDAVP intranasal spray (Stimate®) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A
C Leissinger et al.
HAEMOPHILIA (2001)
Current outcome of portal vein thrombosis in adults: Risk and benefit of anticoagulant therapy
B Condat et al.
GASTROENTEROLOGY (2001)
分享论文
